Myriad Genetics (MYGN) said Wednesday the US Patent and Trademark Office issued two new patents to the company, further advancing the process of its molecular residual disease assay.
US patent No. 12,215,391 relates to proprietary automated methods to carry out molecular residual disease analysis, the company said late Wednesday. Patent No. 12,215,392 relates to the "patient journey" aspects of the disease.
The assay will be able to tell clinicians and patients if the treatment is and if the cancer has recurred, Myriad Chief Executive Paul Diaz said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。